ProGenTech gains $21M in third venture round

ProGenTech, with operations in California and China, has pocketed $21 million in its third round of venture financing. The biotech company markets products for research and medical diagnostics and is developing a contamination free, cassette based automated nucleic acid purification system. Bay City Capital and DT Capital led the round. ProGenTech was founded by two engineers: Steve Yu and Jesus Ching. Yu will remain a director of the company and become its president and COO. Ching will become the chief scientific officer of ProGenTech.

- check out the press release

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.